Tumor virus therapy again received attention to pharmaceutical companies, start-up active plus code.

Medicine Network August 5 - At present, tumor virus immunotherapy has become an important research field in tumor immunotherapy.
, hundred-time Meimei Squibb, Johnson and Johnson, Mersadong and many other large multinational pharmaceutical companies, in recent years through acquisitions or cooperation in this area.
China's pharmaceutical companies, including 3D biology, Tianshili, Yino Micro Pharmaceuticals, Arnold Pharmaceuticals and many other biopharmaceutical companies have also been through independent research or overseas introduction of the way to participate in the development of such drugs.
listed "dissolved tumor" drug is a small number of tumor-soluble viruses, refers to a class of viruses that can effectively infect and destroy tumor cells.
plays a central role in the immunotherapy of tumor virus.
specially designed tumor virus can infect tumor cells, but is weak in normal cytotoxicity.
tumor virus immunotherapy has a dual anti-tumor mechanism: it can not only cause tumor cell lysis death by infecting tumor cells, but also can express tumor-specific immunoactivated proteins, stimulate systemic anti-tumor immune response.
based on these characteristics, tumor virus immunotherapy has been classified as an important branch of tumor immunotherapy.
So far, three antitherapy drugs have been approved for the world, namely recombinant human type 5 adenovirus injections (E1B-55KD, Ancre), Rigvir, imlygic (talimogene laharerpec, T-Vec).
recombinant human type 5 adenovirus injection developed by Shanghai 3D Biological Company, is the use of genetic engineering technology to remove human type 5 adenovirus E1B-55kD gene fragments and E3-19KD gene fragments obtained by a tumor adenovirus, can attack p53 gene deficiency or abnormal tumor cells, and no significant impact on normal human cells.
the drug was approved in China in 2005, the indications are ineffective for conventional radiotherapy or radiotherapy and chemotherapy treatment, and with 5-FU, cisplatin chemotherapy program for palliative care patients with advanced nasopharyngeal cancer.
Rigvir is a genetically modified ECHO-7 enterovirus developed by The Latvian company Latima and was approved in Latvia in 2004 for the treatment of melanoma.
the drug has been approved in several countries, including Poland and Armenia.
it is worth mentioning that during the second Expo in November 2019, Guizhou Shengno Pharma signed a cooperative development agreement with Latima.
under the agreement, the two sides will jointly promote Rigvir's registration declaration and exploratory application in China, and further study new mechanisms and new indications of the fibroid virus to jointly develop the global market.
Imlygic is a genetically modified herpes simplex 1 virus (HSV-1) developed by Amgen that replicates and expresses immunoactivated protein granulocytes-macrophages cluster irritants (GM-CSF) within tumor cells.
inject it directly into the melanoma lesions, which can break tumor cells and release tumor-derived antigens and GM-CSF.
Imlygic was approved in the United States in 2015 for late-stage melanoma, which relapsed after local treatment surgery, and is the first FDA-approved antitherapy drug for the solubility virus.
large multinational drug companies have joined the FDA in 2015 to approve the first solution to the virus immunotherapy drug, this innovative treatment has attracted the attention of many large pharmaceutical companies.
public information shows that in recent years, 100-time Meimei Shiguibao, Johnson and Johnson, Mercadong and many other large multinational pharmaceutical enterprises, have been through the acquisition or cooperation of the way, plus code in this area.
December 2016, Baxter and PsiOxus Therapeutics entered into a cooperation agreement.
BMS obtained PSiOxus Therapeutics' tumor virus immunotherapy candidate NG-348 and paid the latter a $50 million advance payment to fund preclinical research on the drug. in addition
, BMS will pay a milestone of $886 million to support the subsequent development and commercialization of NG-348.
October 2017, AbbVie announced a global research and development cooperation agreement with Turnstone Biologics, which acquired the exclusive development rights of three of the latter's antitherapy drugs for fibroidvirus.
Turnstone was founded in 2015 as a development company focused on the development of next-generation promo virus immunotherapy.
February 2018, Mersadon acquired Viraltics for $394 million through its subsidiary.
Viralytics is a company focused on developing immunotherapy drugs for the virus.
May 2018, Janssen, a Johnson and Johnson-owned company, bought BeneVir Biopharm, a drug research and development company for a solution virus, for $1 billion.
September 2018, Bollinger Ingham bought Vira Therapeutics for 210 million euros.
ViraTherapeutics is a biopharmaceutical company dedicated to the development of immunotherapy drugs for the virus.
December 2019, Takeda and Turnstone, a company focused on the development of tumor immunotherapy, entered into a global cooperative license agreement to jointly develop and promote the latter's new viral immunotherapy drug RIVAL-01.
in addition, many new biopharmaceutical companies are focused on the development of this innovative therapy.
Chinese enterprises actively involved in recent years, many pharmaceutical enterprises in China have also joined the development of antitherapy drugs for lysoma virus.
public information shows that Tianshili, Shengno Pharmaceuticals, Arnold Pharmaceuticals and other companies have been through the "License-in" approach, the introduction of different kinds of products.
, C-REV, introduced by Tasley from Takara Bio, Japan, is a type 1 herpes simplex virus (HSV-1) detoxifying strain that selectively replicates and decomposes tumor cells in tumor cells without damaging normal cells, and C-REV is being developed for the treatment of pancreatic cancer and melanoma. Reolysin, introduced by
Arnold Pharmaceuticals, is a second-generation tumor immunotherapy drug based on the mammalian enterovirus, which kills cancer cells that are overactive by the RAS signaling pathway.
the drug has been granted fast-track status by the FDA for the treatment of metastatic breast cancer.
in addition, there are many pharmaceutical companies choose to independently develop anti-tumor virus immunotherapy drugs, including 3D biology, Tiandakang gene, Dabo Bio, Kanghong Biology, Yino Micromedicine, Binhebio, Renohealthy Bio, Lepu Biology and so on.
3D organisms in addition to the aforementioned approved recombinant human type 5 adenovirus injection, but also on this basis developed H102 (tumor-targeted recombinant adenovirus injection) and H103 (soluble recombinant adenovirus injection), is still in the early stage of research.
Tiandakang Gene, Kanghong Biology, BinheBio, etc. have been approved for clinical research.
Although the use of tumor virus immunotherapy alone has shown clinical activity, the researchers found that using it with immunocheckpoint inhibitors could further enhance the effectiveness of the treatment.
this potential has been validated in clinical trials.
study found that both PD-1 inhibitors and CTLA4 inhibitors, in combination with Imlygic, increased the number of CD8 and CD4-positive T cells in patients, indicating that systemic immune effects may be associated.
, patients with low immunocellular immersion also achieved good results, indicating that "cold tumors" also responded to immunocheckpoint inhibitors under the action of the tumor virus.
According to a review published in June 2018 by Nature Reviews Cancer, there are two potential developments for tumor immunotherapy: one is to combine with T-cell therapy to help T-cells multiply and move in local tumor microenvironments, and to enhance their efficacy, and to further expand their potential by learning more about the immune mechanism.
hopes that as the immune system's anti-tumor mechanism continues to clarify, the study of tumor virus immunotherapy can make more progress and breakthroughs, so that cancer patients have more treatment options.
.